Astrana Health Reports Q4 Revenue of $950.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Should l Buy ASTH?
Reports Q4 revenue $950.5M, consensus $930.46M. "Astrana delivered record revenue, adjusted EBITDA, and free cash flow in 2025, demonstrating the strength and predictability of our fully delegated, payer-agnostic care model and AI-enabled technology platform in a dynamic operating environment," said Brandon Sim, President and CEO of Astrana Health. "Our disciplined approach to risk, strong physician alignment, and technology-enabled clinical infrastructure drove consistent performance while creating measurable value for patients through improved outcomes, greater access, and lower total cost of care. As we move through 2026, with Prospect Health integration ahead of schedule, we are confident in our ability to deliver on guidance that reflects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASTH
Wall Street analysts forecast ASTH stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 20.330
Low
26.00
Averages
33.20
High
40.00
Current: 20.330
Low
26.00
Averages
33.20
High
40.00
About ASTH
Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ASTH Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: ASTH's 52-week low is $18.08 per share, while the high is $34.80, with the last trade at $25.27, indicating the stock's price volatility and reflecting market interest and investor sentiment changes.
- Market Trend Observation: The current price of $25.27 is close to the 52-week median, suggesting a potential recovery in investor confidence, particularly after significant fluctuations, which may attract more investor attention.
- Technical Indicator Reference: ASTH's stock price has crossed above its 200-day moving average, potentially signaling a short-term upward trend, prompting investors to monitor this technical signal for future investment opportunities.
- Investor Sentiment Assessment: Although the current stock price is below the 52-week high, it remains above the low, indicating market recognition of ASTH's potential value, leading investors to seek buying opportunities within this price range.
See More
Astrana Health Reports Record Q4 2025 Earnings and Strong Outlook
- Significant Revenue Growth: Astrana Health reported Q4 2025 revenue of $950.5 million, a 43% year-over-year increase, reflecting the full contribution from Prospect and continued organic growth in the Care Partners segment, showcasing the company's strong performance in the value-based care market.
- Outstanding Annual Performance: Total revenue for 2025 reached $3.2 billion, representing a 56% year-over-year growth and at the high end of the company's guidance range, indicating Astrana's competitive strength and growth potential, with expectations for 2026 revenue between $3.8 billion and $4.1 billion.
- Risk Management Strategy: Management anticipates that by Q1 2026, approximately 80% of revenue and over 36% of membership will be in full-risk arrangements, demonstrating the company's strategic positioning in risk management and market adaptability.
- Shareholder Return Plan: The company announced a repurchase of approximately 634,000 shares at an average price of $22.23 and increased the repurchase program from $50 million to $100 million, reflecting a commitment to shareholders and confidence in future growth.
See More
U.S. Stocks Mixed Amid Iran-U.S. Conflict; Energy Shares Rise
- Mixed Market Performance: U.S. stocks exhibited mixed performance amid the ongoing Iran-U.S. conflict, with the Dow Jones index falling 0.1% to 48,929.19 while the NASDAQ gained 0.37% to 22,751.80, indicating a complex market sentiment.
- Energy Sector Gains: Energy shares rose by 1.8% on Monday, reflecting optimistic expectations for energy demand despite the overall mixed market performance, suggesting strong investor confidence in the energy sector.
- Sealed Air Earnings Beat: Sealed Air Corp (NYSE:SEE) reported fourth-quarter earnings of 77 cents per share, exceeding analyst expectations of 73 cents, with quarterly sales reaching $1.401 billion, surpassing the forecast of $1.342 billion, demonstrating the company's robust profitability.
- International Market Fluctuations: European markets declined broadly, with the STOXX 600 falling 1.65%, reflecting global economic uncertainties, while Asian markets mostly closed lower, indicating investor concerns about future economic prospects.
See More
Astrana Health Reports Strong Quarterly Earnings, Shares Surge
- Earnings Beat: Astrana Health Inc. reported quarterly earnings of 54 cents per share, significantly surpassing the analyst consensus estimate of 11 cents, indicating a strong improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $950.526 million, exceeding the analyst consensus estimate of $930.451 million, demonstrating robust demand for its products and competitive positioning, which may drive future investments and expansion.
- Stock Surge: Astrana Health's shares jumped 29.5% to $26.32 during Monday's session, reflecting a positive investor reaction to the strong earnings report, potentially attracting more institutional investors' interest.
- Market Context: While U.S. stocks were generally lower, with the Dow Jones index falling over 150 points, Astrana Health's strong performance highlights the resilience of individual stocks in uncertain market conditions, possibly providing new investment opportunities for investors.
See More
ASTRANA HEALTH: REPORTS INEFFECTIVE INTERNAL CONTROL OVER FINANCIAL REPORTING AS OF DECEMBER 31, 2025
- Internal Control Issues: ASTRANA HEALTH believes its internal control over financial reporting was not effective as of December 31, 2025.
- Implications of Ineffectiveness: The ineffectiveness in internal controls may impact the reliability of financial statements and overall governance.
See More
Astrana Health Reports Record Financial Results for FY 2025
- Record Financial Performance: Astrana Health achieved a record revenue of $3.18 billion for FY 2025, representing a 56% increase from 2024, demonstrating the resilience of its risk-bearing, technology-driven healthcare model in a dynamic environment, further solidifying its market leadership.
- Significant Adjusted EBITDA Growth: The company reported an adjusted EBITDA of $205 million in 2025, up 20% year-over-year, reflecting that its efficient operational model and strong physician alignment have created measurable value for patients, enhancing accessibility and quality of care.
- Expanded Stock Repurchase Program: The Board of Directors increased the maximum amount for the stock repurchase program from $50 million to $100 million, which is expected to be executed through various methods, aiming to enhance shareholder value and reflect confidence in the company's stock.
- Optimistic 2026 Growth Guidance: Astrana anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, indicating that the integration of Prospect Health is ahead of schedule and will continue to drive sustainable growth moving forward.
See More
ASTH Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: ASTH's 52-week low is $18.08 per share, while the high is $34.80, with the last trade at $25.27, indicating the stock's price volatility and reflecting market interest and investor sentiment changes.
- Market Trend Observation: The current price of $25.27 is close to the 52-week median, suggesting a potential recovery in investor confidence, particularly after significant fluctuations, which may attract more investor attention.
- Technical Indicator Reference: ASTH's stock price has crossed above its 200-day moving average, potentially signaling a short-term upward trend, prompting investors to monitor this technical signal for future investment opportunities.
- Investor Sentiment Assessment: Although the current stock price is below the 52-week high, it remains above the low, indicating market recognition of ASTH's potential value, leading investors to seek buying opportunities within this price range.
See More
Astrana Health Reports Record Q4 2025 Earnings and Strong Outlook
- Significant Revenue Growth: Astrana Health reported Q4 2025 revenue of $950.5 million, a 43% year-over-year increase, reflecting the full contribution from Prospect and continued organic growth in the Care Partners segment, showcasing the company's strong performance in the value-based care market.
- Outstanding Annual Performance: Total revenue for 2025 reached $3.2 billion, representing a 56% year-over-year growth and at the high end of the company's guidance range, indicating Astrana's competitive strength and growth potential, with expectations for 2026 revenue between $3.8 billion and $4.1 billion.
- Risk Management Strategy: Management anticipates that by Q1 2026, approximately 80% of revenue and over 36% of membership will be in full-risk arrangements, demonstrating the company's strategic positioning in risk management and market adaptability.
- Shareholder Return Plan: The company announced a repurchase of approximately 634,000 shares at an average price of $22.23 and increased the repurchase program from $50 million to $100 million, reflecting a commitment to shareholders and confidence in future growth.
See More
U.S. Stocks Mixed Amid Iran-U.S. Conflict; Energy Shares Rise
- Mixed Market Performance: U.S. stocks exhibited mixed performance amid the ongoing Iran-U.S. conflict, with the Dow Jones index falling 0.1% to 48,929.19 while the NASDAQ gained 0.37% to 22,751.80, indicating a complex market sentiment.
- Energy Sector Gains: Energy shares rose by 1.8% on Monday, reflecting optimistic expectations for energy demand despite the overall mixed market performance, suggesting strong investor confidence in the energy sector.
- Sealed Air Earnings Beat: Sealed Air Corp (NYSE:SEE) reported fourth-quarter earnings of 77 cents per share, exceeding analyst expectations of 73 cents, with quarterly sales reaching $1.401 billion, surpassing the forecast of $1.342 billion, demonstrating the company's robust profitability.
- International Market Fluctuations: European markets declined broadly, with the STOXX 600 falling 1.65%, reflecting global economic uncertainties, while Asian markets mostly closed lower, indicating investor concerns about future economic prospects.
See More
Astrana Health Reports Strong Quarterly Earnings, Shares Surge
- Earnings Beat: Astrana Health Inc. reported quarterly earnings of 54 cents per share, significantly surpassing the analyst consensus estimate of 11 cents, indicating a strong improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $950.526 million, exceeding the analyst consensus estimate of $930.451 million, demonstrating robust demand for its products and competitive positioning, which may drive future investments and expansion.
- Stock Surge: Astrana Health's shares jumped 29.5% to $26.32 during Monday's session, reflecting a positive investor reaction to the strong earnings report, potentially attracting more institutional investors' interest.
- Market Context: While U.S. stocks were generally lower, with the Dow Jones index falling over 150 points, Astrana Health's strong performance highlights the resilience of individual stocks in uncertain market conditions, possibly providing new investment opportunities for investors.
See More
ASTRANA HEALTH: REPORTS INEFFECTIVE INTERNAL CONTROL OVER FINANCIAL REPORTING AS OF DECEMBER 31, 2025
- Internal Control Issues: ASTRANA HEALTH believes its internal control over financial reporting was not effective as of December 31, 2025.
- Implications of Ineffectiveness: The ineffectiveness in internal controls may impact the reliability of financial statements and overall governance.
See More
Astrana Health Reports Record Financial Results for FY 2025
- Record Financial Performance: Astrana Health achieved a record revenue of $3.18 billion for FY 2025, representing a 56% increase from 2024, demonstrating the resilience of its risk-bearing, technology-driven healthcare model in a dynamic environment, further solidifying its market leadership.
- Significant Adjusted EBITDA Growth: The company reported an adjusted EBITDA of $205 million in 2025, up 20% year-over-year, reflecting that its efficient operational model and strong physician alignment have created measurable value for patients, enhancing accessibility and quality of care.
- Expanded Stock Repurchase Program: The Board of Directors increased the maximum amount for the stock repurchase program from $50 million to $100 million, which is expected to be executed through various methods, aiming to enhance shareholder value and reflect confidence in the company's stock.
- Optimistic 2026 Growth Guidance: Astrana anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, indicating that the integration of Prospect Health is ahead of schedule and will continue to drive sustainable growth moving forward.
See More
